Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lung biopsy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    582 result(s) found for: Lung biopsy. Displaying page 1 of 30.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-005729-25 Sponsor Protocol Number: LUNGVAC Start Date*: 2022-05-09
    Sponsor Name:Vestre Viken Health Trust
    Full Title: A Randomized Phase II, Open-label, Multicenter Study Investigating Efficacy and Safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced ...
    Medical condition: Inoperable advanced or metastatic non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050017 Lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025044 Lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005614-29 Sponsor Protocol Number: CC-486-NSCL-001 Start Date*: 2015-11-19
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus pembroliz...
    Medical condition: Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) ES (Completed) GR (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002359-27 Sponsor Protocol Number: D5161C00003 Start Date*: 2017-11-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Open-label, Single-arm, Molecular Profiling Study of Patients with EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated with Osimertinib
    Medical condition: EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer not amenable to curative surgery or radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001696-16 Sponsor Protocol Number: SOLUCOM Start Date*: 2021-10-28
    Sponsor Name:Vestre Viken Health Trust
    Full Title: Sotorasib in advanced KRASG12C-mutated non-small cell lung cancer patients with comorbidities
    Medical condition: Advanced KRASG12C-mutated non-small cell lung cancer patients with comorbidities
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025044 Lung cancer LLT
    25.1 100000004850 10069759 KRAS mutation LLT
    22.0 100000004850 10075674 KRAS codon 12 and 13 mutation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005484-28 Sponsor Protocol Number: 20050190 Start Date*: 2006-03-28
    Sponsor Name:Amgen Inc.
    Full Title: A Multicenter, Open Label, Randomized Study of AMG 951 in Subjects with Previously Untreated Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Treated with Chemotherapy with or without Bevacizumab
    Medical condition: Subjects with Previously Untreated Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Treated with Chemotherapy with or without Bevacizumab
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FI (Completed) CZ (Completed) IE (Completed) ES (Completed) NL (Completed) PL (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-006454-30 Sponsor Protocol Number: 23537 Start Date*: 2023-02-09
    Sponsor Name:DIPARTIMENTO DI SCIENZE CHIRURGICHE - UNIVERSITà DEGLI STUDI DI TORINO
    Full Title: Near-infrared molecular imaging for lung cancer detection and treatment during mini-invasive surgery (Phase II Trial)
    Medical condition: To date, lung resection and lymphadenectomy remains the best curative option in patients with early-stage non-small cell lung cancer. Moreover, cancer screening programs have led to a frequent diag...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062042 Lung neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062042 Lung neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003715-38 Sponsor Protocol Number: D4190C00006 Start Date*: 2016-05-12
    Sponsor Name:MedImmune LLC
    Full Title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer
    Medical condition: Locally advanced or metastatic squamous or nonsquamous non- small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003668-32 Sponsor Protocol Number: 2019-BN-001 Start Date*: 2019-12-18
    Sponsor Name:UZ Brussel
    Full Title: A randomized phase II clinical trial of SBRT and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/ CD141 (BDCA-3)+ myeloid dendritic cells in NSCLC
    Medical condition: Oligometastatic solid tumors.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000143-26 Sponsor Protocol Number: VEG105290 Start Date*: 2006-06-06
    Sponsor Name:GlaxoSmithkline S.A.
    Full Title: A Phase II, Non-randomized, Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib (GW786034) as Pre-Surgical Therapy in Treatment-Naïve Subjects with Stage IA or IB, Resectable Non Sma...
    Medical condition: Resectable NonSmall Cell Lung Cancer, Stage IA/IB
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000617-30 Sponsor Protocol Number: MCC-15005 Start Date*: 2008-09-25
    Sponsor Name:Klinik Loewenstein gGmbH
    Full Title: Randomized Phase III Multicenter Trial of RRM1 & ERCC1 Directed Customized Chemotherapy versus Standard of Care for 1st Line Treatment of Patients with Advanced Non-Small-Cell Lung Cancer
    Medical condition: Patients with untreated advanced stage NSCLC. 2:1 randomization to experimental (A) or standard arm (B). In arm A, treatment of dual-agent chemotherapy will be selected based on RRM1 and ERCC1 ex...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005586-75 Sponsor Protocol Number: CSET2014/2204_PIPSeN Start Date*: 2015-10-08
    Sponsor Name:Gustave Roussy
    Full Title: A Randomized double-blind Phase II trial evaluating maintenance olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer
    Medical condition: Advanced non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10025052 Lung cancer non-small cell stage III LLT
    18.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000201-44 Sponsor Protocol Number: IPI-504-14 Start Date*: 2011-08-26
    Sponsor Name:Infinity Pharmaceuticals, Inc
    Full Title: A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated patients with Stage IIIB or IV Non-Small Cell Lung Cancer
    Medical condition: Stage IIIB or IV Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-001264-72 Sponsor Protocol Number: ORH/PID/5298 Start Date*: 2007-05-16
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust
    Full Title: A Phase II Trial of Erlotinib as first line therapy in Non- Small Cell Lung Cancer over-expressing EGFR
    Medical condition: Stage IIIb/IV non-small cell lung cancer (NSCLC) tumours that over-express EGFR
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025054 Lung cancer non-small cell stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013787-39 Sponsor Protocol Number: I2I-MC-JMMD Start Date*: 2009-09-07
    Sponsor Name:Eli Lilly and company
    Full Title: A Phase 2 Study to Evaluate LY2603618 in Combination with Pemetrexed in Patients with Advanced or Metastatic Non-small Cell Lung Cancer
    Medical condition: Advanced or metastatic non-squamous second-line Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 LLT
    9.1 10029522 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020408-31 Sponsor Protocol Number: I2I-MC-JMMG Start Date*: 2010-11-10
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Pemetrexed and Cisplatin in Patients with Stage IV Non-small Cell Lung Cancer
    Medical condition: • Histological diagnosis of Stage IV NSCLC other than predominantly squamous cell histology. • Mesothelioma in advanced or metastatic stage for whom the combination with pemetrexed and cisplatin i...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000307-10 Sponsor Protocol Number: TREM Start Date*: 2015-05-27
    Sponsor Name:Oslo university hospital
    Full Title: AZD9291, an irreversible EGFR-TKI, in relapsed EGFR-mutated non-small cell lung cancer patients previously treated with an EGFR-TKI, coupled to extensive translational studies.
    Medical condition: Locally advanced or metastatic non-small cell lung cancer where disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) DK (Completed) FI (Completed) LT (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003383-51 Sponsor Protocol Number: 2012/VCC/0037 Start Date*: 2013-06-26
    Sponsor Name:Velindre NHS Trust
    Full Title: A randomised phase II trial of Olaparib maintenance versus placebo monotherapy in patients with non-small cell lung cancer
    Medical condition: Non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020229-42 Sponsor Protocol Number: ML21869 Start Date*: 2010-07-18
    Sponsor Name:ROCHE
    Full Title: A randomized phase II trial of erlotinib (TARCEVA) or intermittent dosing of erlotinib and docetaxel in male former smokers with locally advanced or metastatic squamous nonsmall cell lung cancer...
    Medical condition: Non-small cell lung cancer (NSCLC), locally advanced (stage IIIB), metastatic (stage IV) or recurrent.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 PT
    9.1 10029522 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004026-31 Sponsor Protocol Number: CA224-104 Start Date*: 2021-03-22
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Randomized Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Re...
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10025048 Lung cancer non-small cell recurrent LLT
    20.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) AT (Completed) NL (Ongoing) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002555-17 Sponsor Protocol Number: ESR-15-11650 Start Date*: 2017-01-09
    Sponsor Name:AZIENDA OSPEDALIERO - UNIVERSITARIA "POLICLINICO - VITTORIO EMANUELE"
    Full Title: OSIRIS (OSImertinib Rechallenge TKI In Subsequent line of therapy) A Phase II, Noncomparative, Open label, Multicentre, Study of AZD9291, in Patients with Locally Advanced or Metastatic EGFR mutate...
    Medical condition: Locally Advanced or Metastatic EGFR mutated, "T790M undetectable or unknown" Non Small Cell Lung Cancer (Stage IIIB-IV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 06:55:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA